Latest news about Fabtech Technologies
Fabtech Technologies Sets PAT Guidance at 9-11%, Targets ₹1,000 Cr Revenue by 2030
Fabtech Technologies Anticipates Growth in ₹900+ Crore Order Book Driven by Africa Opportunities
Fabtech Technologies
149.46
-0.62(-0.41%)
Company Performance:
View Company Insights1D-0.41%
1M-4.37%
6M-8.27%
1Y-18.06%
5Y-18.06%
More news about Fabtech Technologies
23Jul 26
Fabtech Technologies to discuss Q1 FY27 results on July 28
Fabtech Technologies has announced an earnings conference call for July 28, 2026, at 4:00 PM IST to review the unaudited financial results for the quarter ended June 30, 2026. The session will feature management presentations and a Q&A with executives including the CEO and Chief Growth Officer. Registration is mandatory for participation.
14Jul 26
Fabtech Technologies Secures ₹33.79 Crore in Fresh Orders in June 2026, Order Book Climbs to ₹362.41 Crore
Fabtech Technologies secured new orders totalling ₹33.79 crore in June 2026, taking its total order book to ₹362.41 crore. The company maintains a strong presence in the pharmaceutical and renewable energy sectors. The fresh order wins reflect continued business momentum across its core industrial verticals.
03Jul 26
Fabtech Technologies appoints two independent directors
Fabtech Technologies Limited appointed Ms. Rupal Dhiren Haria and Ms. Bharti Khanna as Non-Executive Independent Directors via a postal ballot. The resolutions secured over 99.99% approval from shareholders, with the e-voting period concluding on June 30, 2026. The scrutinizer's report confirmed the results, which are available on the company's website.
26Jun 26
Fabtech Technologies approves ₹26.49 crore investment in subsidiaries
Fabtech Technologies approved investments totaling ₹26.49 crore in two wholly-owned subsidiaries, Fabtech Technologies LLC and FT Institutions Private Limited, to strengthen market position and expand operations. The board reconstituted the Audit, Nomination and Remuneration, and CSR committees following the completion of Mr. Shyam Nagorao Khante's tenure as Independent Director. Additionally, the board approved an increase in borrowing limits within the provisions of Section 180(1)(c) of the Companies Act, 2013.
26Jun 26
Fabtech Technologies holds investor meet in Mumbai
Fabtech Technologies Limited held an investor meet titled 'The Growth Exchange 2026 – Niveshak Samvad Roadshow' in Mumbai on June 24, 2026. The meeting, which took place from 05:30 p.m. to 06:30 p.m. IST, was restricted to discussions based on publicly available information with no unpublished price-sensitive information disclosed. The disclosure was submitted to the exchanges on June 25, 2026, by Hemant Mohan Anavkar, Executive Director.
24Jun 26
Fabtech Technologies Targets ₹49–52 Cr North Africa Vet Facility, EU GMP Plant; Eyes FY27 Revenue of ₹500 Cr
Fabtech Technologies reported a 25.7% YoY rise in FY26 standalone revenue to ₹410.77 Cr and operational profit of ₹36.60 Cr, backed by an order book exceeding ₹900 Cr. The company is targeting a ₹49.00–52.00 Cr North Africa veterinary facility and an EU GMP plant to support exports, while guiding FY27 revenue of ₹500 Cr and PAT of ₹45 Cr. Its growth strategy spans European acquisitions, joint ventures in Saudi Arabia and Africa, and a margin expansion roadmap targeting PAT margins of 11–13%.
16Jun 26
Fabtech Technologies confirms no encumbrance on promoter shares in FY26
Fabtech Technologies confirmed that its promoters and promoter group did not create any encumbrance on shares held by them during the financial year ended March 31, 2026. The declaration was submitted by Promoter Aasif Ahsan Khan to the NSE and BSE under SEBI takeover regulations. The disclosure covers 66 entities, including individuals and corporate bodies, listed as promoters or promoter group members.
16Jun 26
Fabtech Technologies secures ₹31.23 crore Botswana order
Fabtech Technologies has secured a ₹31.23 crore order from Botswana Vaccine Institute Limited for the design, supply, and installation of HVAC and Clean Room systems at a new veterinary vaccine manufacturing facility. The turnkey contract, awarded on June 15, 2026, involves execution over 14 months and includes GMP-compliant infrastructure.
03Jun 26
Fabtech subsidiary signs agreement for Saudi Arabia entity
Fabtech Technologies announced that its wholly owned subsidiary, Fabtech Technologies LLC, has signed a shareholders agreement to establish Specialized Contracting Activities LLC in Saudi Arabia. The new entity will focus on specialized contracting activities for non-pharma industries, with Fabtech Technologies LLC holding a 51% stake via cash subscription.
31May 26
Fabtech Technologies publishes postal ballot notice in newspapers
Fabtech Technologies Limited has published the postal ballot notice in newspapers dated May 30, 2026, under Regulation 30 of SEBI LODR Regulations. The notice seeks shareholder approval for the appointment of Ms. Rupal Dhiren Haria and Ms. Bharti Khanna as Non-Executive Independent Directors. The remote e-voting facility, managed by NSDL, will be open from June 1, 2026, to June 30, 2026, for members registered as of May 22, 2026.
02May 26
Fabtech Technologies Reports 28.4% Revenue Growth in FY26 Amid Global Challenges
Fabtech Technologies Limited reported strong FY26 results with total income growing 28.4% to ₹431.33 crore and EBITDA rising 18.29% to ₹55.56 crore despite global challenges. The company strengthened its balance sheet through ₹230 crore equity infusion, achieved cash flow positive status, and maintains order book exceeding ₹900 crore with 18-24 months revenue visibility.
30Apr 26
Fabtech Technologies Q4FY26 Results: ₹431.33 Cr Revenue, Management Guidance Update
Fabtech Technologies announced strong FY26 results with ₹431.33 crore revenue and ₹38.36 crore PAT, while providing positive guidance for future growth. Management expects 25-30% order book growth and maintains FY27 revenue targets of ₹530-600 crores with improved operational metrics.
06Apr 26
Fabtech Technologies Submits Q4FY26 SEBI Compliance Certificate to Stock Exchanges
Fabtech Technologies Limited filed its Q4FY26 compliance certificate under SEBI Regulation 74(5) with NSE and BSE on April 06, 2026. The certificate from RTA Bigshare Services Private Limited confirms the regulation is not applicable as all company shares remain in demat form, with no rematerialisation requests received during the quarter ended March 31, 2026.
04Apr 26
Fabtech Technologies Reports Consolidated Order Book Over ₹900 Crore
Fabtech Technologies Limited announced strong business performance with consolidated order book exceeding ₹900 crore as of March 31, 2026. Despite facing global market challenges including logistics disruptions and input cost escalations, the company secured strategic projects across animal health, vaccine, and pharmaceutical sectors in Saudi Arabia and Africa, demonstrating resilience and expanding market presence.
28Mar 26
Fabtech Technologies Appoints Ms. Rupal Dhiren Haria as Independent Director, Reconstitutes Board Committees
Fabtech Technologies Limited appointed Ms. Rupal Dhiren Haria as Additional Non-Executive Independent Director effective April 03, 2026, for five years subject to shareholder approval. The appointment follows completion of Ms. Aparna Narendra Sharma's directorship tenure on April 02, 2026. Ms. Haria, a Chartered Accountant with over 20 years of taxation and auditing experience, will chair two key board committees. The company has reconstituted its Audit Committee, Nomination & Remuneration Committee, and Stakeholder Relationship Committee to reflect the board changes while maintaining regulatory compliance.
24Mar 26
Fabtech Technologies Board Approves Carry Forward of IPO Proceeds to FY 2026-27
Fabtech Technologies Limited's board approved carrying forward unutilized IPO proceeds from FY 2025-26 to FY 2026-27 during a meeting held on March 24, 2026. The company confirmed no deviation from the objects stated in the prospectus dated October 02, 2025, maintaining compliance with SEBI regulations. The decision ensures continued adherence to the original investment plan while providing flexibility in fund deployment timing.
11Mar 26
Fabtech Technologies Clarifies Share Price Movement as Market Driven
Fabtech Technologies Limited responded to stock exchange clarification requests regarding share price movements on March 11, 2026. The company confirmed no pending price-sensitive information exists and attributed price movements to market forces. Executive Director Hemant Mohan Anavkar assured continued compliance with SEBI disclosure requirements.
28Feb 26
Fabtech Technologies Submits Investor Presentation for CVOCA Investocraft 2026
Fabtech Technologies Limited has filed its investor presentation with stock exchanges for the CVOCA Investocraft 2026 meeting, positioning itself as India's global life sciences infrastructure platform targeting medicinal sovereignty projects across continents with a total addressable market of USD 115-140 billion.
14Feb 26
Fabtech Technologies Secures USD 7.05 Million International Contract from West Africa
Fabtech Technologies Limited secured a USD 7.05 million international contract from a West Africa company on February 14, 2026, for supply, installation and commissioning of Oral Solid Dosage facility infrastructure. The project will be executed within 23-27 months from advance receipt, with the client's name withheld due to confidentiality. The contract, worth approximately Rs. 63.6 crores, does not involve related party transactions.
14Feb 26
Fabtech Technologies Q3FY26 Earnings Call Reveals Revenue Timing Issues, Strong Order Book
Fabtech Technologies conducted its Q3FY26 earnings conference call on February 10, 2026, addressing revenue timing challenges while demonstrating strong business fundamentals. The company reported Rs 20.30 crores of deferred revenue due to shipment timing, maintained a robust order book of Rs 926.00 crores as of January 31, 2026, and reaffirmed its FY26 guidance of Rs 380-400 crores revenue with Rs 39-41 crores PAT, targeting 30% growth for FY27.
11Feb 26
Fabtech Technologies Makes Q3FY26 Earnings Call Recording Available Online
Fabtech Technologies Limited has released the recording of its Q3FY26 earnings conference call held on February 10, 2026, featuring key management personnel discussing unaudited financial results for the quarter and nine months ended December 31, 2025. The audio/video recording is now accessible through the company's website and was communicated to stock exchanges in compliance with SEBI regulations.
02Feb 26
Fabtech Technologies Reports Q3FY26 Results with ₹567.79L Loss and Risk Committee Dissolution
Fabtech Technologies announced Q3FY26 results showing consolidated net loss of ₹567.79 lakhs compared to ₹2,045.74 lakhs profit in Q3FY25, with revenue declining 39.84% year-over-year. The Board dissolved the Risk Management Committee and utilized ₹2,350.25 lakhs of IPO proceeds during the quarter.
19Dec 25
Fabtech Technologies Cleanrooms Secures ₹330 Million Order
Fabtech Technologies Cleanrooms has won a significant order worth ₹330 million in the cleanroom solutions sector. This large-scale contract demonstrates the company's capabilities in securing substantial projects and is expected to positively impact its revenue pipeline. The order reinforces Fabtech's competitive position and technical expertise in the specialized cleanroom technology market.
18Nov 25
Fabtech Technologies Clarifies Corporate Identity: Separate from Fabtech Technologies Cleanrooms Ltd
Fabtech Technologies Limited (FTL) has issued a statement to address market confusion, emphasizing its separate identity from Fabtech Technologies Cleanrooms Limited (FTCL). FTL and FTCL are independent, listed companies with distinct management teams and business strategies. FTL focuses on international turnkey life sciences infrastructure across 62 countries, while FTCL primarily serves India's cleanroom infrastructure needs. The companies have different stock listings, symbols, and ISINs. This clarification aims to prevent investor confusion and ensure accurate market representation.
14Nov 25
Fabtech Technologies Reports 109.9% Revenue Growth in H1 FY26, Expands Global Footprint
Fabtech Technologies Limited, a global turnkey engineering solutions provider for pharmaceutical sectors, reported robust H1 FY2026 results. Total income reached INR 19,322.80 lakhs, up 109.9% year-on-year. Net profit increased by 101.6% to INR 2,198.02 lakhs. EBITDA improved to INR 2,839.99 lakhs with margins at 14.7%. The company maintains a strong order book of INR 90,441.87 lakhs as of July 31, 2025, with 7-9% growth from July to September 2025. Operating in 22 countries, Fabtech focuses on MENA, GCC, and ECO Zone regions, offering end-to-end turnkey solutions for pharmaceutical manufacturing. The company's asset-light model and in-house manufacturing capabilities enhance execution agility and cost efficiency.
06Nov 25
Fabtech Technologies Reports Robust Q2 FY26 Results with 109.91% Revenue Growth, Targets Expansion in Bio-Pharma Sector
Fabtech Technologies Limited announced impressive Q2 FY26 results, with total income rising 109.91% YoY to ₹12,427.61 crores. Net profit surged 449.12% to ₹2,810.61 crores, while EBITDA margin expanded to 27.06%. The company's current order book stands at ₹90,441.87 lakhs, with operations across 62 countries. Fabtech is targeting growth in bio-pharma equipment, modular facilities, and engineering turnkey projects, leveraging its expertise in pharmaceutical and healthcare engineering solutions.
05Nov 25
Fabtech Technologies Reports Net Loss in Q1 FY26, Strong Rebound in Q2
Fabtech Technologies Limited reported a significant turnaround in Q2 FY26, with revenue increasing 78.6% to ₹12,148.07 lakhs and net profit reaching ₹2,810.61 lakhs, compared to a loss in Q1. The company completed its IPO and listed on NSE and BSE in October 2025. Additionally, Fabtech secured a ₹52 crore contract for a veterinary formulations facility in North Africa, boosting its order book to ₹983.05 crore. An earnings call is scheduled for November 10, 2025, to discuss Q1 and Q2 FY26 results.
03Nov 25
Fabtech Technologies Secures ₹52 Crore Contract for Veterinary Facility in North Africa
Fabtech Technologies Limited (FTL) has won a ₹52 crore contract to build a veterinary medicines manufacturing facility in North Africa's Maghreb region. The project includes complete design, engineering, cleanroom systems, utilities, and process equipment. This addition boosts FTL's cumulative order book to ₹983.05 crore. The Maghreb veterinary formulation market is projected to reach USD 500-700 million by 2030, driven by increasing demand for animal health products and food security goals. This contract marks FTL's strategic expansion in both human and animal healthcare sectors, leveraging its in-house capabilities to capitalize on growing markets.
Industry Peers
Poly Medicure
Tarsons Products
Q-Line Biotech
Laxmi Dental
Osel Devices
Vasa DenticityFabtech Technologies
Hemant Surgical Industries
Prevest Denpro
Nureca
1,702.00
(+2.09%)
314.60
(-0.58%)
541.30
(+6.17%)
212.69
(+0.37%)
413.05
(-2.14%)
393.75
(-0.71%)
149.46
(-0.41%)
376.00
(+3.01%)
402.00
(+2.81%)
343.60
(+6.64%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
